Antengene announces xpovio® treatment regimens included for the first time in the guidelines for the diagnosis and management of multiple myeloma in china

Shanghai and hong kong , may 18, 2022 /prnewswire/ -- antengene corporation limited ("antengene" sehk: 6996.hk), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announces that the uses of xpovio®(selinexor) for multiple myeloma (mm) patients with first relapse or multiple relapses were incorporated into the guidelines for the diagnosis and management of multiple myeloma in china (2022 revision). this is the first time that selinexor has been included in the guidelines.
KPTI Ratings Summary
KPTI Quant Ranking